LudgerTag Procainamide Glycan Labeling System

Procainamide: A reliable and flexible approach to glycan analysis

Procainamide labeling permits glycan identification by either mass spectrometry or (U)HPLC, and because of its improved ionisation efficiency compared to 2AB labeling it can permit identification of minor glycans (<1% relative peak area) by ESI-MS.

Ludger's procainamide labeling system is suitable for N-glycans, O-glycans, GSL-glycans, heparin or any sugar with a reducing terminus. Also, once labelled with procainamide the glycans can be incubated with exoglycosidases.

As well as labelling kits we offer a clean up system for use after labeling and a range of procainamide labeled glycan standards (including an N-glycan library and glucose homopolymer ladder). Using products together (including LudgerZyme PNGaseF, LZ-rPNGaseF-kit), N-glycan sample preparation can be carried out in one day (for 96 samples)

ludger procainamide labeling timeline

The Table below outlines the features and benefits of Ludger's procainamide labeling technology in comparison to competitor offerings:

Ludger Procainamide Rapid/instant labelling*
Sensitive fluorescence detection for relative glycan quantitation by (U)HPLC ✓✓✓✓✓ ✓✓✓✓✓
Sensitive ESI-MS and MS/MS detection for glycan structural analysis ✓✓✓✓✓ ✓✓✓✓✓
Sample processing speed ✓✓✓ ✓✓✓✓✓
Can label purified glycans and standards? YES NO
Use for O-glycans? YES NO
Use for GSL glycans? YES NO
Similar glycan derivatisation chemistry to 2-AB industry standard? YES NO
Suitable for exoglycosidase sequencing? YES Fluorophore dependent**
* rapid/instant labelling technologies use N-hydroxysuccinimide (NHS) activated fluorophores that react with the glycosylamine form of the glycan
** aminoquinoline labels are not compatible with Bovine Kidney Fucosidase (BKF)

  Product/Ordering Information:

Cat #

N-glycan Analysis:

O-glycan Analysis:


Ludger Publications & Posters

Analytical Chemistry Kozak

Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology.

Crescioli S, Chiaruttini G, Mele S, Ilieva KM, Pellizzari G, Spencer DIR, Gardner RA, Lacy KE, Spicer JF, Tutt ANJ, Wagner GK, Karagiannis SN. J Allergy Clin Immunol. 2018 Apr;141(4):1519-1523.e9. doi: 10.1016/j.jaci.2017.12.986. Epub 2018 Jan 31. No abstract available.

Analysis of Three Epoetin Alpha Products by LC and LC-MS Indicates Differences in Glycosylation Critical Quality Attributes, Including Sialic Acid Content.

Thomson RI, Gardner RA, Strohfeldt K, Fernandes DL, Stafford GP, Spencer DIR, Osborn HMI. Anal Chem. 2017 Jun 20;89(12):6455-6462. doi: 10.1021/acs.analchem.7b00353. Epub 2017 Jun 9.

Variation of Human Salivary O-Glycome.

Kozak RP, Urbanowicz PA, Punyadeera C, Reiding KR, Jansen BC, Royle L, Spencer DI, Fernandes DL, Wuhrer M. PLoS One. 2016 Sep 9;11(9):e0162824. doi: 10.1371/journal.pone.0162824. eCollection 2016.

Comparison of procainamide and 2-aminobenzamide labeling for profiling and identification of glycans by liquid chromatography with fluorescence detection coupled to electrospray ionization-mass spectrometry.

Kozak RP, Tortosa CB, Fernandes DL, Spencer DI. Anal Biochem. 2015 Oct 1;486:38-40. doi: 10.1016/j.ab.2015.06.006. Epub 2015 Jun 12.

Ludger poster

Investigating the role of insect vector glycosylation in African sleeping sickness transmission: Characterisation of procainamide-labelled tsetse fly saliva N-glycans

Kozak RP, Wongtrakul-Kish K, Williams C, Fernandes DL, Perally S, Rose C, Spencer DI, Acosta-Serrano A
Presented at Glyco23: 23rd International Symposium on Glycoconjugates
Split, Croatia, September 2015

Ludger poster

Procainamide labelling as part of a flexible glycoprofiling system for monitoring of Gal-a1-3Gal related Glycosylation Critical Quality Attributes (GCQAs) of monoclonal antibody (mAb) therapeutics throughout the product life cycle

Kozak RP, Royle L, Liew LP, Spencer DI, Fernandes DL
Presented at WCBP 2016: 20th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products
Washington DC, United States, January 2016

Ludger poster

A QbD-compatible approach for reliable measurement of sialic acid O-acetylation as a potential Glycosylation Critical Quality Attribute (GCQA) of erythropoietin (EPO) therapeutics

Fernandes DL, Thomson R, Gardner R, Liew LP, Kozak RP, Royle L, Strohfeldt K, Osborn H, Spencer DI
Presented at WCBP 2016: 20th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products
Washington DC, United States, January 2016


Technical Questions

Dr. Radoslaw P. Kozak

Dr. Radoslaw Kozak
Head of Glycoprofiling

Quotations and Orders

Ludger Procainamide Glycan Labeling System

Sales Team